Trastuzumab resistance accompanies vasculogenic mimicry in HER2-positive breast cancer cells

被引：0
|
作者：
Shimoda, Masafumi [1 ]
Hori, Ami [1 ]
Noguchi, Shinzaburo [1 ]
机构：
[1] Osaka Univ, Grad Sch Med, Suita, Osaka, Japan
来源：
CANCER RESEARCH | 2018年 / 78卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2018-19
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
19
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Mechanisms of Resistance to Trastuzumab and Novel Therapeutic Strategies in HER2-Positive Breast Cancer
    Wong, Andrea L. A.
    Lee, Soo-Chin
    [J]. INTERNATIONAL JOURNAL OF BREAST CANCER, 2012, 2012
  • [32] HER3 activation by MET contributes to trastuzumab resistance in HER2-positive breast cancer
    Hashimoto, Kenji
    Macaulay, Valentine
    Kong, Anthony
    [J]. CANCER RESEARCH, 2014, 74 (19)
  • [33] Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells
    Chi Zhang
    Xuening Duan
    Ling Xu
    Jingming Ye
    Jianxin Zhao
    Yinhua Liu
    [J]. Breast Cancer Research and Treatment, 2012, 136 : 739 - 748
  • [34] Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells
    Zhang, Chi
    Duan, Xuening
    Xu, Ling
    Ye, Jingming
    Zhao, Jianxin
    Liu, Yinhua
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2012, 136 (03) : 739 - 748
  • [35] Predictive factors of resistance to trastuzumab as neoadjuvant therapy in women with HER2-positive breast cancer
    Jinno, Hiromitsu
    Sato, Tomomi
    Takahashi, Maiko
    Hayashida, Tetsu
    Hirose, Shigemichi
    Kitagawa, Yuko
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (26)
  • [36] Albumin-bilirubin score predicts trastuzumab resistance in HER2-positive breast cancer
    Huang, Wen-Juan
    Yuan, Jia-Rui
    Zhang, Lei
    Wang, Wen
    Miao, Shi-Di
    Wang, Xin
    Wang, Rui-Tao
    [J]. CANCER BIOMARKERS, 2023, 38 (04) : 425 - 432
  • [37] Trastuzumab resistance in HER2-positive breast cancer: Mechanisms, emerging biomarkers and targeting agents
    Wang, Zhen-hao
    Zheng, Zhuo-qun
    Jia, Shi-cheng
    Liu, Shu-ni
    Xiao, Xiao-fen
    Chen, Guan-yuan
    Liang, Wei-quan
    Lu, Xiao-feng
    [J]. FRONTIERS IN ONCOLOGY, 2022, 12
  • [38] CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer
    Fei Xing
    Hongli Gao
    Guanglei Chen
    Lisha Sun
    Jiayi Sun
    Xinbo Qiao
    Jinqi Xue
    Caigang Liu
    [J]. Molecular Cancer, 22
  • [39] Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
    Piccart-Gebhart, MJ
    Procter, M
    Leyland-Jones, B
    Goldhirsch, A
    Untch, M
    Smith, I
    Gianni, L
    Baselga, J
    Bell, R
    Jackisch, C
    Cameron, D
    Dowsett, M
    Barrios, CH
    Steger, G
    Huang, CS
    Andersson, M
    Inbar, M
    Lichinitser, M
    Láng, I
    Nitz, U
    Iwata, H
    Thomssen, C
    Lohrisch, C
    Suter, TM
    Ruschoff, J
    Süto, T
    Greatorex, V
    Ward, C
    Straehle, C
    McFadden, E
    Dolci, MS
    Gelber, RD
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (16): : 1659 - 1672
  • [40] Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
    von Minckwitz, Gunter
    Procter, Marion
    de Azambuja, Evandro
    Zardavas, Dimitrios
    Benyunes, Mark
    Viale, Giuseppe
    Suter, Thomas
    Arahmani, Amal
    Rouchet, Nathalie
    Clark, Emma
    Knott, Adam
    Lang, Istvan
    Levy, Christelle
    Yardley, Denise A.
    Bines, Jose
    Gelber, Richard D.
    Piccart, Martine
    Baselga, Jose
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (02): : 122 - 131
12345